Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Leuk Lymphoma. 2019 Jan 10;60(8):1934–1941. doi: 10.1080/10428194.2018.1563691

Table 2:

Outcome and Risk Factors of Randomized Patients to Transplant

# Status Arm Survival
(days)
Age Bulky Stage Symptoms IPI2 Sex LDH BM
Involved
Extranodal Histology Cause of
Death
1. A Refused 2954 29 No III B HI M NL N N ALCL, ALK(+)3
2. A BCV 2639 61 No III A HI F High N Y PTCL4
3. A TBI 4624 54 No III B H F High Y Y ANGIO5
4. A TBI 2863 27 Yes IV B H M High N Y PTCL
5. A TBI 3976 46 No IV A HI M N N Y ALCL, ALK(−)
6. A TBI 3173 58 No III A HI M High N N ALCL,ALK(+)
7. D Refused 311 48 No IV B HI M High Y Y PTCL UNK
8. D MF1 282 60 No III B HI M High N N ALCL,ALK(−) SEPSIS6
9. D BCV 1408 51 No III A HI M High N N ALCL,ALK(−) UNK
10. D BCV 156 26 No IV B HI M NL N Y ALCL,ALK(+) NHL
11. D BCV 438 51 No IV B H M High N Y ALCL,ALK(−) NHL
12. D BCV 310 37 No IV B HI M High Y Y PTCL SHOCK6
13. D BCV 427 59 No III A HI F High N N PTCL UNK
14. D BCV 641 65 No III A HI M High N N ANGIO NHL
15. D TBI 319 59 Yes IV B HI M High N Y PTCL NHL
1

Mobilization Failure

2

HI:Hiqh Intermediate; H: High

3

ALCL (Anaplastic, ALK (+) or (−))

4

Peripheral T Cell Lymphoma

5

Angioimmunoblastic

6

Related to treatment for relapse

HHS Vulnerability Disclosure